BioSpace News Archive

Tetraphase Pharmaceuticals, Inc. announced that senior management will present a corporate overview at the H. C. Wainwright and Company Global Life Sciences Conference on Monday, April 8, 2019 at 9:10 a.m. GMT at the Grosvenor House JW Marriott Hotel in London, UK and at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 2:50 p.m. ET at the Westin Grand Central Hotel in New York City.

Cerus Corporation announced the closing of a new debt facility with MidCap Financial which is expandable up to $90 million.

Pierre Fabre will have exclusive commercialization rights for NERLYNX in European countries excluding Russia and Ukraine, along with countries in North Africa and francophone countries of West Africa.

LabCorp® announced that its Zero Coupon Convertible Subordinated Notes due 2021 may be converted as set forth below.

Aaron Sato, Ph.D., Chief Scientific Officer of Twist Biopharma, to Deliver Keynote Address

InVivo today reported financial results for the year ended December 31, 2018.

Randomized, 12-Month, Pivotal Trial Evaluating the Safety and Efficacy of Patidegib Topical Gel to Reduce the Disease Burden of Chronic BCCs in Patients with Rare Form of Skin Cancer

Zelnorm works differently than other prescription treatments for IBS-C by inducing intestinal contraction and relaxation.

HUM Nutrition, the leading beauty vitamin and supplement company, announces the launch of Skin Heroes, the first pre+probiotic that specifically targets the gut-skin axis, formulated for acne-prone (non-cystic) and dry skin.

Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) today announced results from the Phase 3 ADMIRAL clinical trial comparing XOSPATA® (gilteritinib) to salvage chemotherapy in adult patients with relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FLT3 mutation